COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Treatment of Egyptian Hepatitis C Genotype 4 Infected Children (and Adolescents) With Combined Sofosbuvir & Daclatasvir

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03080415
Recruitment Status : Completed
First Posted : March 15, 2017
Last Update Posted : June 6, 2018
Egyptian Cure Bank
Society of Friends of Liver Patients in the Arab World (SLPAW)
Information provided by (Responsible Party):
Dr. Tawhida Yassin Abdel Ghaffar, Yassin Abdelghaffar Charity Center for Liver Disease and Research

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : February 18, 2018
Actual Study Completion Date : May 18, 2018
(CDER) USDoHaHSFaDACfDEaR. Guidance for Industry Chronic Hepatitis C Virus Infection: Developing Direct-Acting Antiviral Drugs for Treatment 2013. Available from: http://www.fda. gov/downloads/drugs/guidancecomplianceregulatoryinformation/ guidances/ucm225333.pdf